•
•
•
•
•
•
•
•
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Fintel
100%
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Low Data
Fintel reports that on October 23, 2024, Baird downgraded their outlook for McDonald's (NYSE:MCD) from Outperform to Neutral.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Country
US
Industry
Health Care
Market Cap
Mid Cap
Num. Employees
70
IPO Date
Jul 29, 2021
Country
US
Industry
Health Care
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 70 full-time employees. The company went IPO on 2021-07-29. Its lead product candidate, NVL-520 is a novel ROS1-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases. Its second lead product candidate, NVL-655, is a brain-penetrant ALK-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first, second, and third generation ALK inhibitors. The Company’s product candidate also includes NVL-330, is a brain-penetrant HER2-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20, treating brain metastases, and avoiding treatment-limiting adverse events, including due to off-target inhibition of wild-type EGFR.
Related Stocks
Related Stocks
Stocks being mentioned with NUVL